Royalty-free licenses let you pay once to use copyrighted images and video clips in personal and commercial projects on an ongoing basis without requiring additional payments each time you use that ...

neuro.med.kyushu-u.ac.jp Background: Granulysin, a recently defined cytolytic molecule, is expressed in cytotoxic T cells and natural killer cells in a similar way to perforin, which is reported to ...

ULSCs is under clinical development by RESTEM and currently in Phase I for Polymyositis. According to GlobalData, Phase I drugs for Polymyositis does not have sufficient historical data to build an ...

RESTEM Receives FDA Orphan Drug Designation for its ULSC Program for the Treatment of Polymyositis and Dermatomyositis Restem Tue, Dec 3, 2024, 8:00 AM 3 min read ...

Patients with polymyositis had a higher risk for atherosclerotic cardiovascular disease when compared against those with dermatomyositis or dermatopolymyositis. Patients with idiopathic inflammatory ...

The Polymyositis drugs in development market research report provides comprehensive information on the therapeutics under development for Polymyositis, complete with analysis by stage of development, ...

Recent findings regarding interferon and Janus kinase inhibition may hold clues to improving outcomes in patients with complex myositis, according to a presenter at the Biologic Therapies Summit ...

1 Department of Rheumatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China 2 Department of Rheumatology, Zhongshan Hospital Fudan University, Shanghai, China ...

Belonging to the same group of autoimmune diseases, both dermatomyositis and polymyositis cause muscle inflammation and weakness. But dermatomyositis also affects your skin and is more likely to ...